Background 

When bladder cancer is found early, before it spreads into the deeper muscle of the bladder, it is called non-muscle invasive bladder cancer (NMIBC). Doctors usually treat it by removing the tumor from inside the bladder and then placing medicine directly into the bladder to kill any remaining cancer cells and prevent the cancer from coming back. The most common treatment, called BCG, is made from a weakened form of a tuberculosis vaccine. However, there is currently a worldwide shortage of BCG, and even when it is available, it stops working for about half of patients within two years. When BCG fails, many patients are told that bladder removal surgery is the next step, which can be life-changing and difficult. 

What the Study Proposes to Address 

Researchers are studying a new, more affordable treatment that uses two common chemotherapy drugs, gemcitabine and docetaxel, placed directly into the bladder one after the other. This treatment can be used as a replacement for BCG or for patients whose cancer has come back after BCG. Other similar “two-drug” treatments are also showing promise, but right now, doctors don’t have a way to know which drug combination will work best for each individual patient. This study aims to develop a personalized tool that can help predict which drug pair will be most effective. The team will test small samples of each patient’s tumor in the lab to see how it reacts to different drugs and drug combinations. They will also study the tumor’s genes to learn which genetic changes are linked to successful treatment. In addition, they plan to develop a urine test that can detect tumor DNA and show whether the treatment is working and how much cancer may still be present. 

Why This Research is Important 

This research could lead to a major breakthrough in how doctors choose the best treatment for patients with early-stage bladder cancer. Instead of a “one-size-fits-all” approach, each patient could receive a therapy tailored to their unique cancer. The new urine test could also give doctors a simple way to track how well the treatment is working without needing repeated invasive procedures. Ultimately, this study could help patients avoid bladder removal surgery, reduce cancer recurrence, and improve quality of life—all while using affordable, widely available medications. 

None Reported as of August 2025

None Reported as of August 2025

Kristina Thiel, PhD; University of Iowa